Handelsbanken Fonder AB lowered its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 94.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,251 shares of the health services provider's stock after selling 97,800 shares during the period. Handelsbanken Fonder AB's holdings in Amedisys were worth $594,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC boosted its holdings in Amedisys by 40.4% during the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider's stock valued at $250,000 after acquiring an additional 757 shares during the period. Contravisory Investment Management Inc. bought a new stake in shares of Amedisys during the fourth quarter valued at approximately $258,000. Argonautica Private Wealth Management Inc. boosted its stake in Amedisys by 6.1% during the third quarter. Argonautica Private Wealth Management Inc. now owns 3,003 shares of the health services provider's stock worth $280,000 after acquiring an additional 172 shares in the last quarter. Federated Hermes Inc. raised its holdings in Amedisys by 32.9% in the fourth quarter. Federated Hermes Inc. now owns 3,518 shares of the health services provider's stock worth $334,000 after buying an additional 871 shares during the last quarter. Finally, MRP Capital Investments LLC bought a new position in Amedisys during the 3rd quarter valued at about $337,000. Institutional investors own 94.36% of the company's stock.
Analyst Ratings Changes
Several analysts recently issued reports on AMED shares. StockNews.com cut Amedisys from a "buy" rating to a "hold" rating in a research report on Friday, April 26th. Royal Bank of Canada lifted their target price on Amedisys from $97.00 to $100.00 and gave the stock an "outperform" rating in a report on Monday, March 25th. Cantor Fitzgerald restated a "neutral" rating and issued a $101.00 price target on shares of Amedisys in a research report on Thursday, April 25th. Finally, Raymond James reissued a "market perform" rating on shares of Amedisys in a research note on Tuesday, March 26th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $97.50.
Get Our Latest Research Report on AMED
Amedisys Price Performance
Shares of NASDAQ:AMED traded down $0.16 during midday trading on Wednesday, reaching $91.89. 221,966 shares of the company's stock traded hands, compared to its average volume of 274,448. The company has a market cap of $3.00 billion, a P/E ratio of -143.59, a PEG ratio of 3.42 and a beta of 0.86. The company has a fifty day simple moving average of $92.48 and a two-hundred day simple moving average of $93.34. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.09. Amedisys, Inc. has a 1 year low of $73.10 and a 1 year high of $96.44.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company had revenue of $571.41 million during the quarter, compared to analysts' expectations of $565.38 million. During the same period in the prior year, the business earned $1.00 EPS. The firm's quarterly revenue was up 2.7% on a year-over-year basis. Equities analysts predict that Amedisys, Inc. will post 4.57 EPS for the current fiscal year.
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
